Clinical Trial Update: Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 trial update of apatinib for relapsed and refractory diffuse large B-cell lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Zhengzhou University | Conditions: Relapsed and Refractory, Diffuse Large B Cell Lymphoma | Phase 4 | Status: COMPLETED